Literature DB >> 17215292

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines.

Zsolt Fábián1, Christine M Csatary, József Szeberényi, Laszlo K Csatary.   

Abstract

While Newcastle disease virus (NDV) causes serious infections in birds, it is apparently nonpathogenic in mammalian species, including humans. Previous observations and small-scale clinical trials indicated that NDV exerts oncolytic effects. Isolates of NDV were found to have selective affinity to transformed cells. We previously showed that the attenuated NDV strain MTH-68/H causes apoptotic cell death in cultures of PC12 rat pheochromocytoma cells. The aim of the present study was to extend MTH-68/H cytotoxicity testing with human tumor cell lines and to analyze certain biochemical aspects of its oncolytic effect. MTH-68/H was found to be able to kill a wide range of transformed cells by apoptosis. While caspase-8 and caspase-9 are not involved in MTH-68/H-induced apoptosis, activation of caspase-3 and caspase-12 was detected in virus-infected PC12 cells. A human glioblastoma cell line with repressible expression of the p53 protein did not show any difference in MTH-68/H sensitivity in its p53-expressing and p53-depleted states, indicating that the apoptotic process induced by MTH-68/H does not depend on p53. Apoptosis was accompanied by virus replication in two tumor cell lines tested (PC12 cells and HeLa human cervical cells), and signs of endoplasmic reticulum stress (phosphorylation of protein kinase R-like endoplasmic reticulum kinase and eIF2alpha) were also detected in transformed cells. In contrast, proliferation of nontransformed mouse and rat fibroblast cell lines and human primary fibroblasts was not affected by MTH-68/H treatment. MTH-68/H thus selectively kills tumor cell cultures by inducing endoplasmic reticulum stress leading to p53-independent apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215292      PMCID: PMC1865991          DOI: 10.1128/JVI.02490-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells.

Authors:  D W Meek; W Eckhart
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  Treatment of human cancer with mumps virus.

Authors:  T Asada
Journal:  Cancer       Date:  1974-12       Impact factor: 6.860

3.  The proteins of Newcastle disease virus. 1. Structural proteins.

Authors:  D J Alexander; P Reeve
Journal:  Microbios       Date:  1972 May-Jun

4.  Radiation-induced apoptosis: effects of cell age and dose fractionation.

Authors:  C C Ling; M Guo; C H Chen; T Deloherey
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

5.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Newcastle disease virus selectively kills human tumor cells.

Authors:  K W Reichard; R M Lorence; C J Cascino; M E Peeples; R J Walter; M B Fernando; H M Reyes; J A Greager
Journal:  J Surg Res       Date:  1992-05       Impact factor: 2.192

7.  A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray; H S Phillips
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

8.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Authors:  W B Isaacs; B S Carter; C M Ewing
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

9.  Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.

Authors:  M Reiss; D E Brash; T Muñoz-Antonia; J A Simon; A Ziegler; V F Vellucci; Z L Zhou
Journal:  Oncol Res       Date:  1992       Impact factor: 5.574

10.  In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.

Authors:  W Liebrich; P Schlag; M Manasterski; B Lehner; M Stöhr; P Möller; V Schirrmacher
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  32 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.

Authors:  Chun-Xiao Zhang; Long-Wei Ye; Ying Liu; Xiao-Ya Xu; Dan-Rui Li; Yan-Qing Yang; Lu-Lu Sun; Jie Yuan
Journal:  Tumour Biol       Date:  2015-04-16

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.

Authors:  Udaya S Rangaswamy; Weijia Wang; Xing Cheng; Patrick McTamney; Danielle Carroll; Hong Jin
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

5.  Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Authors:  Gerd R Silberhumer; Peter Brader; Joyce Wong; Inna S Serganova; Mithat Gönen; Segundo Jaime Gonzalez; Ronald Blasberg; Dmitriy Zamarin; Yuman Fong
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

6.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

Review 7.  The therapeutic effect of death: Newcastle disease virus and its antitumor potential.

Authors:  Sara Cuadrado-Castano; Maria T Sanchez-Aparicio; Adolfo García-Sastre; Enrique Villar
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

8.  The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin.

Authors:  Itay Lazar; Barak Yaacov; Tamar Shiloach; Elad Eliahoo; Luna Kadouri; Michal Lotem; Riki Perlman; Zichria Zakay-Rones; Amos Panet; Dina Ben-Yehuda
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 9.  Endoplasmic reticulum stress in disease pathogenesis.

Authors:  Jonathan H Lin; Peter Walter; T S Benedict Yen
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Expression of transgenes from newcastle disease virus with a segmented genome.

Authors:  Qinshan Gao; Man-Seong Park; Peter Palese
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.